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Summary
Background: Impressive in vitro research in rodents and
computational modeling has uncovered the core mechanisms
responsible for generating neuronal oscillations. In particular,
GABAergic interneurons play a crucial role for synchronizing
neural populations. Do these mechanistic principles apply to
human oscillations associated with function? To address
this, we recorded ongoing brain activity using magnetoen-
cephalography (MEG) in healthy human subjects participating
in a double-blind pharmacological study receiving placebo,
0.5 mg and 1.5 mg of lorazepam (LZP; a benzodiazepine upre-
gulating GABAergic conductance). Participants performed a
demanding visuospatial working memory (WM) task.
Results: We found that occipital gamma power associated
with WM recognition increased with LZP dosage. Importantly,
the frequency of the gamma activity decreased with dosage,
as predicted by models derived from the rat hippocampus. A
regionally specific gamma increase correlated with the drug-
related performance decrease. Despite the system-wide phar-
macological intervention, gamma power drug modulations
were specific to visual cortex: sensorimotor gamma power
and frequency during button presses remained unaffected.
In contrast, occipital alpha power modulations during the
delay interval decreased parametrically with drug dosage, pre-
dicting performance impairment. Consistent with alpha oscil-
lations reflecting functional inhibition, LZP affected alpha
power strongly in early visual regions not required for the
task demonstrating a regional specific occipital impairment.
Conclusions:GABAergic interneurons are strongly implicated
in the generation of gamma and alpha oscillations in human
occipital cortex where drug-induced power modulations pre-
dicted WM performance. Our findings bring us an important
step closer to linking neuronal dynamics to behavior by
embracing established animal models.
Introduction
The human ability to encode, maintain, and manipulate visual
representations requires a strict temporal coordination of
neuronal activity. Numerous investigations point to oscillatory
brain activity playing an important role in cognition [1],
including one of the most important cognitive operations:
working memory (WM). Impressive in vitro animal models
have shown that GABAergic interneurons are intimately*Correspondence: ole.jensen@donders.ru.nlinvolved in the mechanisms producing neuronal synchroniza-
tion, especially the gamma band (30–100 Hz) [2, 3]. This
notion is supported by exhaustive experimental work in rat
hippocampus slices demonstrating that pharmacological
GABAergic enhancement increases the amplitude of sponta-
neous gamma oscillations while decreasing the frequency
[4–7]. These gamma modulations can be mechanistically
explained by a prolongation of the time course of inhibitory
postsynaptic currents (IPSC) caused by the GABAergic
enhancement. As a consequence, the inhibitory period, which
determines the gamma frequency, increases. Although these
oscillatory mechanisms have been extensively investigated
in animal models, such as brain-slice preparations of the rat
hippocampus, the link to function is highly limited. It is not
known whether the same physiological mechanisms apply to
human brain oscillations and, most importantly, whether they
support human WM operations.
Visuospatial WM requires the encoding and retention of
neuronal representations as well as recognition. Neuronal syn-
chronization in the gamma band has been associated with the
processing of visual stimuli and attention in monkeys and hu-
mans [8]. Specifically, gamma power and coherence increase
with the spatial allocation of attention ([9, 10], but see [11]) and
are predictive of response times to visual stimuli [10]. On the
other hand, during rest, GABAergic neurotransmission is
implicated in the generation of oscillatory activity in the alpha
band (8–14 Hz) in animals [12] and humans [13, 14]. Function-
ally, the alpha band has been linked to the allocation of compu-
tational resources by inhibiting regions not required for a given
task [15, 16].
In short, recent evidence supports the notion that gamma
band activity is involved in active processing, whereas alpha
oscillations reflect the allocation of neuronal resourcesby func-
tional inhibition. In thepresent study,wehaveusedmagnetoen-
cephalography (MEG) to investigatewhether theanimalmodels
for gamma and alpha oscillations generalize to humans. Here,
by pharmacologically manipulating the GABAergic efficacy
with lorazepam (LZP), we ask whether inhibitory interneurons
are involved in producing the WM-related gamma and alpha
band activity and its consequences for behavior.
Results
We performed a double-blind randomized crossover design in
which healthy participants received either placebo or LZP at
two different doses (0.5 mg and 1.5 mg). LZP is a common
benzodiazepine that binds allosterically to GABAA receptors
and enhances chloride conductance by increasing its chan-
nel-opening frequency [17]. We used MEG to measure the
ongoing brain activity while subjects performed a delayed
match-to-sample visuospatial WM task [18] (Figures 1A and
1B). Each trial started by presenting a centrally presented
visual cue for 1.5 s. The task was to encode the sample array
composed of colored squares presented in the cued hemifield
while maintaining central fixation. After a 1.5 s delay interval, a
probe array was presented, and participants had to indicate
whether it matched the sample array or not. Prior to the MEG
experiment, we had assessed the participants WM capacity.
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Figure 1. Experimental Design and Behavioral
Results
(A) The timing of the drug administration (see
Supplemental Experimental Procedures for de-
tails).
(B) The working memory (WM) task. Each trial
started by presenting a cue (left or right arrow)
in the center of the screen for 1.5 s. Participants
had to encode a sample array of colored squares
in the cued hemifield while maintaining central
fixation. After a 1.5 s delay interval, a probe array
was presented, and participants had to indicate
whether it matched the sample array. ‘‘Match’’
and ‘‘nonmatch responses’’ were assigned using
the right index and middle finger, respectively.
The probe stimulus remained on the screen until
the participant responded (maximum of 2 s).
(C) The accuracy (hits plus correct rejections
divided by total responses) decreased as a func-
tion of drug dosage.
(D) The Kspan (Pashler), an index that estimates
the memory span when considering the errors,
decreased with drug dosage. The hit and false
alarm rates are also shown as blue and red lines,
respectively (right y axis scale).
(E) The reaction times increased as a function of
drug dosage.
LZP, lorazepam; VAS, visual analog scale; P,
physiological measure (blood pressure and pulse
rate).
*p < 0.05, **p < 0.01, ***p < 0.005, yp < 5 3 1024.
Error bars show the SEM.
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2879This allowed us to have the participants performwith accuracy
close to 75%, matching task difficulty (for details, see Supple-
mental Experimental Procedures available online).
Importantly, head position showed no systematic differ-
ences over the three experimental sessions (F2, 48 = 0.69, p =
0.45; Figure S1; see Supplemental Experimental Procedures
and [19]). Although performance decreased with LZP, (see
below), it did not influence performance in a control task
(WM load 1, Figure S2) or drowsiness as measured by subjec-
tive questionnaire tests as a function of dosage (visual analog
scales or the placebo-drug scale, Figure S3).
LZP Decreases Performance and WM Capacity
We first set out to investigate the behavioral consequences of
LZP. Performance was assessed by considering Kspan (a mea-
sure of the effective memory span when considering hits and
false alarm rates) and accuracy (Figure 1C). Regarding the
Kspan, we found a strong main effect of drug (F2, 48 = 9.77,
p < 5 3 1024; placebo = 0.5 mg LZP: t24 = 1.73, p = 0.09; pla-
cebo > 1.5 mg LZP: t24 = 4.39, p < 0.001; 0.5 mg LZP >
1.5 mg LZP: t24 = 2.7, p < 0.02; Figure 1D), explained by a
decrease in hit rate (F2, 48 = 9.78, p < 5 3 10
24) without false
alarm rate change with LZP (F2, 48 = 1.14, p = 0.33; Figure 1D).
As expected, LZP resulted in an increase in reaction times
(F1.5, 35.6 = 6.16, p < 0.01; placebo = 0.5 mg LZP: t24 = 20.02,
p = 0.98; placebo < 1.5 mg LZP: t24 = 22.43, p < 0.05; 0.5 mg
LZP < 1.5 mg LZP: t24 =23.88, p < 0.005; Figure 1E). Similarly,
LZP decreased d prime without impact response bias (Fig-
ure S4). In conclusion, LZP produced a WM performance
impairment accompanied by an increase in reaction times.
LZP Increases Stimulus-Induced Gamma Power
Here, we askedwhether GABAergic neurotransmission plays a
role in the generation of human gamma activity bycharacterizing how stimulus-induced gamma activity as
measured by MEG is affected by LZP. First, we calculated
the time-frequency representations (TFRs) of power in the
gamma band (40–150 Hz). We observed strong stimulus-
induced gamma activity over occipital sensors in response
to the sample (0.1–0.35 s) and probe (1.75–2.15 s) periods in
all drug conditions (Figures 2A–2C). Using a beamformer
approach, we localized the sources of the gamma activity to
occipital cortex with maxima in primary visual cortex.
Next, we asked whether the stimulus-induced gamma band
activity was modulated by LZP by considering a set of poste-
rior sensors (marked sensors in Figure 2 topography plots; see
Supplemental Experimental Procedures for sensor selection).
We constructed pairwise scatterplots comparing the different
drug conditions over participants (Figure 2D). Clearly, LZP
increased the stimulus-induced gamma power during the
probe period in most participants, as also confirmed by a Wil-
coxon signed-rank test. Also, during the sample interval, the
LZP resulted in an increase in stimulus-induced gamma power
(F2, 48 = 3.75, p < 0.05; placebo < 0.5 mg LZP: t24 = 22.29, p <
0.05; placebo < 1.5 mg LZP: t24 =22.56, p < 0.05; 0.5 mg LZP =
1.5 mg LZP: t24 =20.89, p < 0.38; Figure 2E).The same pattern
was observed in the probe interval (F2, 48 = 6.13, p < 0.005; pla-
cebo < 0.5 mg LZP: t24 =22.4, p < 0.05; placebo < 1.5 mg LZP:
t24 =22.89, p < 0.05; 0.5 mg LZP = 1.5 mg LZP: t24 =21.87, p =
0.07; Figure 2F). Finally, the gamma power in contralateral
hemisphere was stronger in comparison with ipsilateral hemi-
sphere, regardless of LZP dose for both the sample arrays
(Figure 2G) and the probe arrays (Figure 2H). As control anal-
ysis, we tested whether there were systematic gamma power
differences between the drug sessions in the baseline interval
(20.5 s to20.1 s), but this was not the case (F1.1, 26.8 = 1.89, p =
0.18). Despite the strong stimulus-induced gamma power in-
crease, the LZP dosage did not modulate the degree of
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Figure 2. High-Frequency LZP-Induced Power Modulations during the WM
Task
(A) Placebo session. Left: topographic representation of the stimulus-
induced relative gamma (60–90 Hz) power during the probe interval
(1.75–2.15 s). Color code represents relative power changes with respect
to the baseline (20.5 s to 20.1 s). Middle: averaged power time-frequency
representations (TFRs) over selected occipital sensors (marked in topo-
graphic representations). Time t = 0 s indicates sample array onset.
Dashed rectangles indicate the time and frequency selections for the sta-
tistical analysis. Right: sources of the gamma band activity obtained using
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2880gamma band modulation as induced by the cue (F2, 48 = 0.25,
p = 0.77; Figure S5).
In sum, we found that gamma power during sample and
probe increased with LZP dosage. However, the cue-induced
hemispheric lateralization in the gamma band did not system-
atically change with drug.The Gamma Power that Increased with LZP Predicted
Increased Reaction Times
Do the changes in gamma power with LZP explain the
changes in behavior? To explore this, we correlated the
drug-related changes in gamma power with the drug-related
changes in performance. When considering the gamma po-
wer in occipital sensors contralateral to the attended visual
hemifield, we found a positive correlation with reaction times
between 0.5 mg LZP and placebo (rspearman = 0.42, p < 0.05;
Figure 2I). No significant correlations were found between
1.5 mg LZP and reaction time (rspearman = 0.3, p = 0.14; Fig-
ure 2J) or any other behavioral index. Further, we did not
find an effect in sensors ipsilateral to the cued hemifield.
Summarizing, the increase in reaction time with 0.5 mg LZP
dosage (but not with 1.5 mg) was predicted by a drug-related
increase of contralateral gamma power in response to the
probe.Gamma Frequency Decreased with LZP
Experiments on hippocampal slices have shown that an
increase in inhibitory conductance by pharmacological
GABAergic enhancement decreases gamma frequency [4–7].
We sought to test whether this finding generalizes to the hu-
man visual stimulus-induced gamma response. To quantify
potential frequency changes in the power spectra, we first
computed the TFR of the relative change in stimulus-induced
gamma during probe presentation (Figure 3A). We observed
that the power in the gamma band shifted toward lower fre-
quencies (<75 Hz) with LZP. This is also observed when aver-
aging over the 1.8–1.95 s probe array interval (Figure 3B). Toa beamformer approach morphed onto a Montreal Neurological Institute
(MNI) standard brain. The peak of the source was in occipital cortex (probe
versus baseline; cluster-based nonparametric permutation test, p < 0.001,
controlled for multiple comparisons). The color code represents the rela-
tive power masked by significant grid points within the cluster. The sen-
sors marked in the topographical representations are the sensors of inter-
est used in the subsequent analysis.
(B and C) Stimulus-induced gamma power increase for 0.5 mg lorazepam
(LZP) and 1.5 mg LZP, respectively (same conventions as in A).
(D) Scatterplots of the stimulus-induced gamma power; each dot corre-
sponds to a participant. Wilcoxon signed-rank test revealed that the stim-
ulus-induced gamma power increased with LZP dosage. The top right
frequency histogram was constructed by summing the scatterplot values
within diagonally oriented bins.
(E and F) Repeated-measures ANOVA confirmed that the LZP-induced
gamma power increased during both the sample and the probe intervals.
Error bars show SEM.
(G and H) The stimulus-induced gamma power was stronger in sensors
contralateral to the attended side for both sample and probe periods. Error
bars show SEM.
(I) Correlation between drug-related modulations of stimulus-induced
gamma power and reaction times. The y axis is the reaction time differ-
ence between the 0.5 mg LZP sessions minus the placebo sessions,
and the x axis represents the difference between stimulus-induced contra-
lateral gamma power for 0.5 mg LZP minus placebo (each dot represents a
participant).
(J) Correlation for 1.5 mg LZP session (same conventions as in I).
*p < 0.05, **p < 0.01, ***p < 1025.
A B
C
Figure 3. The Gamma Frequency Decreased with
LZP Dosage
(A) Induced power TFRs in selected occipital sen-
sors (marked sensors in topography in Figure 4,
same conventions) during the probe interval. A rela-
tive baseline was applied (20.5 s to20.1 s). Time t =
1.6 s indicates probe stimuli onset.
(B) Gamma power spectra computed in the 1.8–
1.95 s interval (black rectangles in A) for each
drug session.
(C) Scatterplots of the gamma center-of-mass fre-
quency (Hz); each dot represents a participant. Wil-
coxon signed-rank test showed a significant
gamma frequency decrease with LZP.
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mass’’ index (see Supplemental Experimental Procedures)
applied to the 50–100 Hz range around the peak in the probe
interval defined above. A Wilcoxon signed-rank test revealed
that 1.5 mg LZP significantly reduced the gamma frequency
in comparison with placebo (z = 22.68, p < 0.01) and 0.5 mg
LZP (z = 22.6, p < 0.01). We did not observe a difference be-
tween 0.5 mg LZP and placebo (z = 20.55, p = 0.58). We
conclude that the dominant frequency in the gamma band fre-
quency decreases with LZP dosage.
As gamma frequency decreases with LZP, one might
wonder whether individual gamma frequencies correlate with
WM capacity or whether the reduction in WM capacity is pre-
dicted by the slowing of the gamma frequency. We addressed
this by correlating the gamma frequency (center of mass) with
the maximum WM capacity (Kspan) measured during the
behavioral experiment in session 1. There was no significant
correlation between Kspan and gamma frequency in any of
the sessions (placebo rspearman = 0.09, p = 0.64; 0.5 mg LZP
rspearman = 0.07, p = 0.73; 1.5 mg LZP rspearman = 0.18, p =
0.37). Further, when comparing the drug sessions, there
were no significant relationships between the WM capacity
reduction and the gamma frequency slowing with neither
0.5 mg LZP (rspearman = 0.14, p = 0.50) nor 1.5 mg LZP
(rspearman = 0.08, p = 0.71).
LZP Leaves Gamma Activity in Motor Cortex Unaffected
To further determine the brain region specificity of our pharma-
cological manipulation, we explored the oscillatory dynamics
in sensorimotor cortex during the button-press response.
Recent human studies have reported on gamma activity inmo-
tor cortical areas [20, 21]. To this end,wecalculated theTFRsof
power, whichwere time locked to participants’ button presses.
This revealedgammaactivity at the timeof themotor response.
Contrary to visual areas, the motor-related gamma power was
not affected by LZP (F2, 48 = 0.78, p = 0.46; Figure 4). Likewise,
absolute gamma power during baseline period (20.5 s to
20.3 s) was not statistically different (F1.1, 28.5 = 0.85, p =
0.81), discarding thepossibility that systematic changesduring
thepremovement period could explain the null effect. These re-
sults demonstrate that the pharmacological manipulation spe-
cifically affected gamma band activity in the visual cortex.Modulation of Occipital Alpha Power Is
Reduced by LZP
We then set out to examine how brain ac-
tivity in the lower-frequency bands
(<40 Hz) was modulated by LZP. TFRs of
power were calculated for individual trialsand then averaged with respect to spatial attention condition
(left or right) for each MEG session separately. We first consid-
ered themodulationwith respect to spatial attention. Amodula-
tion index (MI) was calculated as the normalized power
difference between the attention left versus right trials [22]:
MI = (powerattention left 2 powerattention right) / (powerattention left +
powerattention right). Importantly, the same denominator for
all drug sessions was used in the normalization (i.e.,
powerattention left +powerattention right fromtheplacebocondition).
As shown in Figure 5, alpha band activity was strongly modu-
lated by spatial attention throughout the task. It was reduced
contralateral to the direction of attentionwhile it increased rela-
tively over the ipsilateral hemisphere (Figures 5A–5C, left and
right columns). Source reconstruction using a beamforming
approach revealed that the alpha power wasmodulatedmainly
in occipital regions (Figures 5A–5C, center column).
To identify sensors of interest that showed oscillatory power
modulations as a function of allocation of attention, we pooled
all MEG sessions and conducted a cluster-based nonpara-
metric permutation test applied to the cue period (21 s to
20.1 s) in the alpha band (9–13 Hz) (see Supplemental Exper-
imental Procedures). For these sensor groups (see Figures 5A–
5C, topographical plots, bold circles), we averaged theMI with
attention over the left and the right hemisphere (absolute
value) and tested the influence of LZP during the delay period
(0.5–1.4 s). In addition, we constructed pairwise scatterplots
comparing the different drug conditions over participants.
These plots revealed that the alpha MI decreased with drug
dosage in most participants, as confirmed by the Wilcoxon
signed-rank test (Figure 5D). The parametric reduction inmod-
ulation with dosage was further confirmed by repeated-mea-
sures ANOVA (F1.4, 34.3 = 11.95, p < 5 3 10
24; placebo >
0.5 mg LZP: t24 = 2.9, p < 0.01; placebo > 1.5 mg LZP: t24 =
3.84, p < 0.005; 0.5 mg LZP > 1.5 mg LZP: t24 = 3.01, p <
0.01; Figure 5E), with both hemispheres being affected by
LZP in a nondifferent way. Similar statistical conclusions
were found using within-session total power as a denominator
(F2, 48 = 6.35, p < 0.005). Complementarily, for each participant,
we fitted regression lines to the alpha MI for each session us-
ing categorical values (1, 2, and 3) to represent LZP dosages.
This resulted in negative slopes significantly different from
zero (20.015 6 0.004; t24 = 23.84, p < 0.001), supporting the
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Figure 4. High-Frequency LZP-Induced Power Modulations during Button
Press
(A) Left: topography of button-pressed relative gamma power (60–90 Hz)
around the button press (20.1–0.1 s). Color code represents relative
changes with respect to the baseline (20.5 s to 20.3 s). Right: averaged
TFRs of power over selected left sensorimotor sensors (marked sensors
in topography). Time t = 0 s indicates participant’s button press. Dashed
lines indicate the baseline interval and button-press period.
(B and C) Induced gamma power for 0.5 mg LZP and 1.5 mg LZP, respec-
tively (same conventions as in A).
(D) Cluster of significant gamma power modulations around the button
presses (cluster-based nonparametric permutation test; p < 0.02, corrected
for multiple comparisons). Color code based on t values when comparing
the button press to baseline.
(E) LZP did not modulate sensorimotor gamma power. Error bars show
SEM.
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2882notion that the decrease in alpha power with LZP was highly
robust.
In short, we found that posterior alpha band activity was
modulated as a function of spatial allocation of attention dur-
ing WM maintenance and that this modulation was reduced
with LZP dosage.
The Decrease in Alpha Power Modulations with LZP
Predicts WM Impairment
Next, we investigated the modulations in alpha power by LZP
in relation to WM performance. To do so, we correlated the
drug-related alpha MI changes (combined over hemispheres)
with the drug-related performance changes over participants
(combined over hemifields). We found a positive correlation
between the alpha MI reduction and the decrease in Kspan
when comparing 0.5 mg LZP to placebo (rspearman = 0.60, p <0.005; Figure 5F). This was also the case when comparing pla-
cebo with 1.5 mg LZP (rspearman = 0.45, p < 0.05; Figure 5G). To
conclude, the participants with the strongest memory-related
impairment were the ones with the strongest alpha MI
reductions.
LZP Interacts with Alpha Power in Ipsilateral and
Contralateral Hemispheres
Is the decrease in alpha MI by LZP mainly explained by alpha
modulations in the hemisphere ipsilateral or contralateral to
the cued hemifield? WM impairment could be a consequence
of a failure to inhibit distracting visual information as reflected
by ipsilateral alpha power. To investigate this issue, we
computed the absolute alpha power in ipsilateral and contra-
lateral sensors during the delay interval for all dosages sepa-
rately. This revealed that the absolute alpha power during
the delay interval in ipsilateral hemisphere was stronger than
that in contralateral hemisphere (F1, 24 = 35.5, p < 53 10
26; Fig-
ure 6). Strikingly, as seen in Figure 6, the 3 3 2 repeated-mea-
sures ANOVA revealed a significant drug 3 hemisphere inter-
action (F1.6 38.4 = 6.07, p < 0.01; Figures 6D and 6E),
suggesting that LZP impacted alpha power in ipsilateral hemi-
sphere differently compared to contralateral hemisphere. This
was explained by LZP strongly reducing the alpha power in the
ipsilateral hemisphere to the cued visual hemifield (ipsi pla-
cebo > ipsi 0.5 mg LZP: t24 = 3.15, p < 0.01; ipsi placebo >
ipsi10.5 mg LZP: t24 = 6.43, p < 5 3 10
26; ipsi 0.5 mg LZP >
ipsi 1.5 mg LZP: t24 = 5.09, p < 10
24) in comparison to the
contralateral power (contra placebo > contra 0.5 mg LZP:
t24 = 2.26, p < 0.05; contra placebo > contra 1.5 mg LZP:
t24 = 4.44, p < 5 3 10
24; contra 0.5 mg LZP > contra 1.5 mg
LZP: t24 = 5.28, p < 5 3 10
25; Figures 6D and 6E). The present
interaction was specific to the delay interval; it was not
observed in the cue interval (F2, 48 = 0.82, p = 0.44).
As for alpha MI, for each participant, we fitted regression
lines to ipsilateral and contralateral hemispheric alpha power
using categorical values to represent LZP concentrations.
Both the ipsilateral (20.07 6 0.01; t24 = 26.43, p < 5 3 10
26)
and contralateral (20.06 6 0.01; t24 = 25.28, p < 5 3 10
25)
slopes were significantly different from zero. Importantly, the
regression slopes were significantly more negative in sensors
in the ipsilateral hemisphere compared to the contralateral
hemisphere (t24 = 22.82, p < 0.01). We also tested whether
the absolute power correlated with the alpha MI over subjects;
this was not the case. In addition, the individual drug-related
changes in alpha MI did not correlate with the drug-related
changes in absolute alpha power during the delay interval.
In sum, LZP reduced alpha power in the ipsilateral hemi-
sphere more so than in the contralateral hemisphere during
the delay interval of the WM task.
Gamma and Alpha Attentional Power Modulations
Correlate over Participants
So far, we have demonstrated that gamma and alpha power
are modulated as a function of spatial attention (Figures S4
and 5A–5C, respectively). Does the alpha modulation in the
delay interval predict the gamma modulation during the probe
delay? To test this, we correlated over participants the alpha
MI during the delay interval with the gamma MI during the
probe interval for each MEG session separately (using the
MIs combined over hemispheres). We found a significant
negative correlation during placebo (rspearman = 20.42, p <
0.05) and 1.5 mg LZP (rspearman =20.42, p < 0.05), but not dur-
ing 0.5 mg LZP (rspearman = 20.31, p = 0.13; Figure S6). This
−25% 25%
-10% 10%0
Placebo
10
20
30
40
Left hemisphere
cue sample delay probe
−15%
0
 15%
10
20
30
40
Right hemisphere
cue sample delay probe
−1.5 0 1.5
Time (s)
−1.5 0 1.5
Time (s)
Fr
eq
ue
nc
y 
(H
z)
0.5mg LZP
10
20
30
40
10
20
30
40
1.5mg LZP
10
20
30
40
10
20
30
40
Fr
eq
ue
nc
y 
(H
z)
Fr
eq
ue
nc
y 
(H
z)
A
Placebo 0.5mg LZP 1.5mg LZP
F(1.4, 34.3) = 11.95; p < 5 x 10-4
5
10
α 
M
I (
%
)
**
*
*
E
B
C
−1.5 0 1.5
Time (s)
−1.5 0 1.5
Time (s)
−1.5 0 1.5
Time (s)
−1.5 0 1.5
Time (s)
D
0 10 20 30
0.
5m
g 
LZ
P
α
M
I (
%
)
Placebo α MI (%) 
Signrank test: 
p < 0.005; z = −3.21
0 10 20 30
1.
5m
g 
LZ
P
α 
M
I (
%
)
Placebo α MI (%)
Signrank test: 
p < 0.005; z = −3.24
0 10 20 30
1.
5m
g 
LZ
P
 α
 M
I (
%
)
0.5mg LZP α MI (%) 
Signrank test: 
p < 0.05; z = −2.33
rspearman = 0.60; p < 0.005 rspearman = 0.45; p < 0.05 
−0.8
−0.4
0
0.4
0.8
K
sp
an
 0
.5
m
g 
LZ
P
−P
la
ce
bo
−1
−0.8
−0.6
−0.4
−0.2
0
0.2
0.4
K
sp
an
 1
.5
m
g 
LZ
P
−P
la
ce
bo
−10 −5 0 5 10 −15 −10 −5 0 5
α MI (%) 0.5mg LZP−Placebo α MI (%) 1.5mg LZP−Placebo
F G
M
I
MI
 z=14mm
 z=22mm
 z=22mm
Figure 5. Low-Frequency LZP-Induced Power
Modulations during WM Task
(A) Placebo session. Averaged TFRs shown by
the alphamodulation index (MI) over left and right
occipital sensors (marked sensors in topog-
raphy). Color code represents the modulation in
power with attention (normalized difference for
left minus right attention). Time t = 0 s indicates
sample array onset. Middle above: MI topog-
raphy for the time and frequency ranges indi-
cated by the dashed rectangles (9–13 Hz; 0.5–
1.4 s). Middle below: alpha sources producing
the MI obtained with a beamforming approach
morphed to an MNI standard brain. The peak of
the source was located in occipital cortex (atten-
tion left versus attention right; cluster-based
nonparametric permutation test; p < 0.02,
controlled for multiple comparisons). The color
code represents the alpha MI of significant grid
points. Themarked sensorswere used in the sub-
sequent analysis.
(B and C) The alpha MI for 0.5 mg LZP and 1.5 mg
LZP, respectively (same conventions as in A).
(D) Scatterplots of the alpha MI during the delay
period; each dot corresponds to a participant.
Wilcoxon signed-rank tests shows that the alpha
MI significantly decreased with LZP dosage.
(E) The main effect during and alpha MI show a
highly robust decrease. Error bars show SEM.
(F) Participants with a strong drug-related
decrease in alpha MI were also participants with
a strong decrease inWMcapacity. The y axis rep-
resents the Kspan difference between the 0.5 mg
LZP sessions minus the placebo sessions, and
the x axis represents the difference between
alpha MIs for 0.5 mg LZP minus placebo (each
dot represents a participant).
(G) Correlation for 1.5mg LZP session (same con-
ventions as in G).
*p < 0.01, **p < 0.005.
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2883means that the participants with a stronger alpha power mod-
ulation during retention (positive MI) are also those with a
stronger gamma power modulation in the reverse direction
during probe processing (negativeMI). These findings suggestthat alpha bandmodulation reflects top-
down control, which is predictive of the
gamma band activity reflecting feedfor-
ward processing.
Discussion
We used MEG to investigate how the
GABAergic allosteric modulator LZP in-
fluences human oscillatory brain activity
during WM operations. We show for the
first time in humans that stimulus-
induced gamma power increases while
frequency decreases due to the
enhancement of inhibitory conductance
by the selective enhancement of GABAA
receptors. The drug-related increase in
occipital gamma power contralateral to
the attended hemifield was predictive
of increases in response times. Even
though LZP modulates GABAA recep-
tors brain-wide, sensorimotor gammaactivity was not modulated by LZP, i.e., the effect in the
gamma band was specific to the visual cortex. Oscillations in
the alpha bandwere strongly lateralized according to direction
of attention during the memory delay: they decreased in
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Figure 6. Drug-Related Alpha Power Changes in
the Hemispheres Contralateral and Ipsilateral to
the Cued Direction
(A) Placebo session. Left: absolute power in the
hemisphere ipsilateral to the attended visual field.
Both topographic plots (delay period: 0.521.4 s;
alpha power: 9213 Hz) and TFRs represent power
for occipital sensors shown (marked in topograph-
ical plot). Time t = 0 s indicates sample array onset.
Right: similar plots for effects contralateral to the
attended visual hemifield.
(B and C) 0.5mg and 1.5mg LZP sessions, respec-
tively (same conventions as in A).
(D) The absolute alpha power during the delay
period decreased systematically with drug in
both the hemisphere contralateral to the cue and
the hemisphere ipsilateral to the cue. Further, the
decrease ipsilateral to the cue was stronger than
the decrease contralateral to the cue, yielding a
significant interaction, as revealed by repeated-
measures ANOVA. Error bars show SEM.
(E) The difference in absolute alpha power when
comparing the different drug conditions for
contralateral and ipsilateral hemisphere to cue. A
pairwise post hoc t test showed that alpha abso-
lute power in the ipsilateral hemisphere was
more suppressed with LZP in comparison to the
contralateral hemisphere. Error bars show SEM.
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array, whereas they increased relatively in ipsilateral regions.
The alpha band lateralization was reduced with LZP dosage,
and furthermore, it predicted WM performance. Our findings
strongly implicate GABAergic interneurons in the regulation
and generation of gamma and alpha activity, respectively, dur-
ing human WM operations.
GABAergic Modulations of Gamma Oscillations
Our findings show that human visual gamma power and fre-
quency are modulated by an increase in GABAA neurotrans-
mission. Although previous studies have implicated GABA in
generating gamma band activity associated with visual stimu-
lation, the findings are mixed. Recent MEG studies reported a
gamma power increase with the GABAA receptor agonist pro-
pofol [23], but not with the GABA reuptaker inhibitor tiagabine
[24]. The decrease in gamma frequency with LZP has not been
reported in other studies applying GABAergic allosteric mod-
ulators in humans [23, 24] but has been shown in rat and mon-
key visual cortex under anesthesia [25, 26]. In addition, the
administration of alcohol (GABA and NMDA modulator) did
produce a decrease in gamma frequency during visualstimulation [27]. Finally, a recent study
combining magnetic resonance spec-
troscopy (MRS) and MEG found a rela-
tionship between gamma frequency and
GABA concentration [28], although the
reliability of the findings have been chal-
lenged very recently [29].
In our study, sensorimotor gamma po-
wer changes locked to the button press
were not modulated by the drug [20,
21]. In a recent study on humans in which
acetylcholine was enhanced, an effect
on gamma power in visual, but not
sensorimotor, regions was reported[30]. Furthermore, it should be emphasized that the concentra-
tion of GABA receptors is disproportionally high in the occipital
cortex, as measured by PET [31]. We concluded that the phys-
iological mechanisms of sensorimotor gamma activity differ
from the mechanisms of visual gamma activity. As such, our
findings are the first to report a robust increase in gamma
band activity in a WM task associated with a frequency
decrease due to GABAA enhancement.
Which mechanisms might explain the increase in gamma
power and the decrease in frequency with LZP? The physio-
logical mechanisms behind gamma oscillations have been
extensively studied by in vitro work in the rat hippocampus
[2, 3]. This work has demonstrated that GABAergic interneu-
rons play a critical role for the rhythmic synchronization on
neuronal populations in the gamma band. It has been demon-
strated that gamma power increases as a function of IPSP
([4–6], but see [7]). Also, the increases in IPSPs result in a pro-
longation of the gamma cycle, thus reducing the gamma fre-
quency [4–7]. Two mechanisms have been proposed for
generating gamma oscillations: the interneuronal network
gamma (ING) and the pyramidal-interneuronal network
gamma (PING) mechanism. In ING models, inhibitory
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2885interneurons are necessary and sufficient for generating
gamma oscillations [6], whereas in PING, the gamma oscilla-
tions are a consequence of the interplay between pyramidal
and inhibitory interneurons [32]. Because MEG recordings
cannot tell cell types apart [33], we cannot distinguish whether
a PING or an ING mechanism dominates. However, in a recent
nonhuman primate study, Vinck et al. [34] analyzed intracrani-
ally recorded single-unit activity in association with gamma
oscillations in V4. They applied a spike-waveform analysis to
sort the cells in broad spiking (BS) and narrow spiking (NS)
neurons, i.e., putative pyramidal neurons and inhibitory cells,
respectively. The firing BS neurons preceded the NS neurons
by 3.3 ms while both were locked to the phase of the gamma
as identified in the local field potential. This finding supports
the PING model and might generalize to the human gamma
band activity.
The Functional Role of Gamma Oscillations
We observed that gamma band activity was strongest contra-
lateral to the direction of attention during visual stimulation.
Previously, studies have implicated gamma oscillations in vi-
sual processing and neuronal communication [35]. For
instance, it has been proposed that gamma band synchroniza-
tion results in a stronger feedforward drive to downstream
visual regions [36–38]. We propose that the gamma band syn-
chronization we observed during the sample and probe inter-
vals reflects encoding and recall of the attendedmemory array
involving early visual areas. Importantly, the increase in
gamma power with LZP does not predict better performance.
We conclude that although the gamma band synchronization
might reflect the encoding visual stimuli, it does not neces-
sarily mean that more gamma power is predictive of better
performance.
GABAergic Modulation of Alpha Oscillations
It is well established that alpha power recorded during rest is
reduced with GABAergic agonists ([13, 14], but see [39, 40]).
We now extend these findings by demonstrating that the
modulation of alpha power also is robustly reduced during
WM maintenance. High alpha power has been proposed to
reflect reduced vigilance. Because we find that LZP de-
creases alpha power while performance is reduced, it is clear
that the magnitude of alpha power does not simply equate
lack of vigilance.
What are the mechanisms explaining the decrease in alpha
power with LZP? One simple explanation is that LZP increases
GABAergic inhibition and reduces the pyramidal firing without
affecting oscillatory frequency per se. This interpretation is
consistent with an in vitro study applying diazepam: although
this GABAergic agonist decreases the number of spikes per
burst, it leaves the burst rate unaffected [41]. Another not
mutually exclusive possibility is the involvement of the thal-
amus in the generation of alpha oscillations. Whereas the
alpha activity measured with MEG is most likely produced by
sources in the deeper layers of neocortex [42, 43], the neocor-
tical alpha sources have been found to be coupled to thalamic
generators [12, 44, 45]. These findings have been used to
constrain physiologically realistic computational models of
the alpha rhythm [46]. As such, themodulation in alpha activity
with LZP might have a thalamic origin as well.
Given the proposed inhibitory role of the alpha band activity
[15, 16], one might have expected the alpha power to increase
as the GABAergic inhibition increases. Because we obtained
the reverse finding, the dynamics are evidently morecomplicated than that. Future intracranial animal recordings
would be required to gain full insight into this issue.
In future research, it would be interesting to uncover
whether it is actually the GABAergic modulation of frontal or
subcortical sources causing the changes in posterior alpha
band activity. Given that it is problematic to detect deeper
sources with MEG, this could be done in a combined EEG/
fMRI. Drug-specific effects in relation to the alpha activity
could then be investigated in regions potentially involved in
the control of the alpha activity (dorsal attention network, pul-
vinar, and striatum).
The Functional Role of the Alpha Band Oscillations
It has been proposed that alpha band activity reflects the allo-
cation of computational resources [15, 16]. Basically, a
regional-specific increase in alpha power reflects functional in-
hibition, whereas a decrease reflects engagement. This inhibi-
tion might be crucial for distracter suppression, ensuring the
integrity of the WM representations [47, 48]. Our findings are
fully consistent with this notion. Consistently, LZP produced a
stronger reduction in alpha power suppression over ipsilateral
hemisphere incomparisonwith thesuppression incontralateral
hemisphere during the delay period, not during the cue. We
interpret this finding as a pharmacological task-specific effect
on alpha oscillations that cannot be accounted for by a general
decrease in vigilance (i.e., the same power decrease would be
expected in ipsilateral and contralateral hemispheres).
Conclusions
Altogether, the results presented here suggest that the same
GABAergicphysiologicalmechanism forneuronalgammaoscil-
lations uncovered by hippocampal ratmodels applies to human
visual brain oscillations during WM processing. Because the
modulations in the alpha band were present during the cue
and delay intervals, we propose that alpha oscillations reflect
top-down processing (see also [38]). The gamma band activity
mainly occurred during the presentation of the memory array
and probe and is therefore likely to be dominated by feedfor-
ward processing. Our data underscore an important role of
GABAergic neurotransmission for neuronal synchronization on
both gamma and alpha band oscillations. As such, our findings
bring us an important step closer to linking neuronal dynamics
to human behavior by embracing established animal models.
Experimental Procedures
Thirty-two healthy participants gave informed consent approved by the
local research ethics committee (Commissie Mensgebonden Onderzoek;
Arnhem-Nijmegen, number: 2011/199, date: August 5, 2011) and were
compensated for their participation. Data from seven participants were re-
jected (see Supplemental Experimental Procedures for rejection criteria),
leaving a total of 25 participants. They were all right-handed and had normal
or corrected-to-normal vision (mean age: 22.4, range: 18–28 years old,
12 males; see Supplemental Experimental Procedures and Figure 1A for
complete experimental design and general pharmacological procedure).
We adapted a classical delayed match-to-sample visuospatial WM task
[18] while ongoing brain activity was recorded using awhole-headMEGsys-
tem with 275 axial gradiometers (VSM/CTF Systems). Data were analyzed
offline using FieldTrip [49] (http://fieldtrip.fcdonders.nl/), an open-source
toolbox developed at the Donders Institute for Brain, Cognition, and
Behavior, and custom MATLAB code (MathWorks).
Supplemental Information
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.cub.2014.10.017.
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